{"id":"flotufolastat-18f","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This radiopharmaceutical is designed to target folate receptor-positive tumors by mimicking folate and binding to folate receptors that are overexpressed on many cancer cell types. The fluorine-18 radiolabel enables PET imaging to visualize and localize folate receptor-expressing lesions in patients with suspected or known malignancies. This allows for improved detection, staging, and monitoring of folate receptor-positive cancers.","oneSentence":"Flotufolastat (18F) is a fluorine-18 labeled folate analog that binds to folate receptors on cancer cells for positron emission tomography (PET) imaging.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:36.747Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"PET imaging of folate receptor-positive tumors in oncology patients"}]},"trialDetails":[{"nctId":"NCT07025369","phase":"PHASE2","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-25","conditions":"Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT07164027","phase":"EARLY_PHASE1","title":"Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-11-14","conditions":"Prostate Carcinoma","enrollment":30},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT07285057","phase":"PHASE2","title":"Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-02-10","conditions":"Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma","enrollment":120},{"nctId":"NCT07393867","phase":"PHASE2","title":"Androgen-responsive POSLUMA-guided Intra-prostatic Boost","status":"NOT_YET_RECRUITING","sponsor":"Martin T. King, MD, PhD","startDate":"2026-03","conditions":"Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer","enrollment":23},{"nctId":"NCT06881823","phase":"PHASE1, PHASE2","title":"Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2026-06-29","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT06105918","phase":"PHASE1","title":"Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2023-11-29","conditions":"Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":6},{"nctId":"NCT07220720","phase":"PHASE2","title":"POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-11-04","conditions":"Prostate","enrollment":30},{"nctId":"NCT05779943","phase":"PHASE2","title":"Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2023-04-27","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma","enrollment":20},{"nctId":"NCT06389786","phase":"NA","title":"Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-11","conditions":"Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8","enrollment":50},{"nctId":"NCT04186845","phase":"PHASE3","title":"Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2020-05-04","conditions":"Prostate Cancer","enrollment":391},{"nctId":"NCT06604442","phase":"PHASE4","title":"Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy","status":"COMPLETED","sponsor":"Blue Earth Diagnostics","startDate":"2024-12-04","conditions":"Prostate Cancer","enrollment":55},{"nctId":"NCT06580015","phase":"NA","title":"[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-03-25","conditions":"Prostate Carcinoma","enrollment":20},{"nctId":"NCT06865768","phase":"PHASE2","title":"An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-04-18","conditions":"Prostate Carcinoma","enrollment":90},{"nctId":"NCT05852041","phase":"EARLY_PHASE1","title":"rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-06-07","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8","enrollment":40},{"nctId":"NCT06813898","phase":"EARLY_PHASE1","title":"An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-02-17","conditions":"Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Flotufolastat (18F)","genericName":"Flotufolastat (18F)","companyName":"Blue Earth Diagnostics","companyId":"blue-earth-diagnostics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flotufolastat (18F) is a fluorine-18 labeled folate analog that binds to folate receptors on cancer cells for positron emission tomography (PET) imaging. Used for PET imaging of folate receptor-positive tumors in oncology patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}